Pentraxin3 and nitric oxide-associated with an atherogenic index and type II diabetes mellitus

Abstract

This study concentrated on evaluation pentraxin3, as well as Nitric oxide and their correlation with atherogenic index (AI) in Diabetes mellitus II. The current study includes 30 control subjects(group I), and60 Iraqi patients with type II diabetes mellitus(T2DM).The patient group was subdivided in to two groups: group II (30) Newly diagnosed T2DM and group III(30) T2DM (how were treating with metformin monotherapy). In the present study pentraxin3, Nitric oxide was measured by enzyme linked immune sorbent assay (ELISA). Biochemical parameters, fasting serum glucose, insulin, HbA1c,and lipid profile were measured through spectrophotometer technique in patients and control groups. The current study showed significant increase in levels of FSG, HbA1c, BMI, WHtR, TC, TG, LDL, VLDL while HDL level was decrease in Newly diagnosed DM, whereas insulin appeared non-significant deference. A high significant increase in Nitric oxidelevels in diabetic with metformin therapygroup, significantincrease in pentraxin3innewly diagnosed diabetic group.Positive significantly correlation coefficient between pentraxin 3 and HbA1c.,atherogenic index and negative significantly correlation with HDL, while there was no significant correlation between pentraxin 3 and nitricoxide. Effect of gender was significant of Nitric oxide inNewly diagnosed diabetic group and control group, whilepentraxin3 showednon significant effect of gender in all studied groups. Atherogenic index positively correlated with pentraxin3.Metformin therapy increasenitric oxide significantly, while non-significant effect was shown with pentraxin3.